Home' Australian Pharmacist : Australian Pharmacist May 2015 Contents Australian Pharmacist May 2015 I ©Pharmaceutical Society of Australia Ltd.
Items in the Product news section are prepared from information provided by the companies named in each
item. They are included for the information of PSA members. It is up to the individual member to use their
professional judgment to decide on the merit or otherwise of each product mentioned. PSA neither endorses
nor confirms claims made in the items. (Where provided by the company references citing evidence are
included with the items.)
Australian Pharmacist is a professional journal. It will carry only advertising which is likely to be of interest to all
pharmacists and which does not reflect unfavourably directly or by implication on the pharmacy profession or
the professional practice of pharmacy. Advertising which does not comply with this policy will be refused. It is
the responsibility of the advertisers to comply with the relevant Commonwealth and State law. Advertising does
not constitute an endorsement by PSA of the claims, products or services.
Read in greater detail more regularly than any other pharmacy title –
such constant behaviour means you can count on our readers to open
any issue and be seen!
» Greatest number of recipients opening and reading (82%)
» Greatest number of readers reading every issue (48%)
Engage with almost 18,800 PSA members every month (15,500
pharmacists in print and 16,000 in digital form).
» Australian Pharmacist is read by 65% of community pharmacists
It has an extremely strong CPD program followed by more than 10,000
pharmacists – a typical monthly article receives 3000 plus assessments,
with highs over 4000!
» Greatest average proportion read (73%)
» Circulation 14,872 cab March 2013
TO ADVERTISE in the best-read pages in pharmacy media and give your campaign real
impact, and greater recognition, contact Tremain Media.
Ph: 02 9988 4689
Ph: 02 9547 3001
Ph: 02 9871 5520
*Competitive Advantage Research August 2012 – 632 practicing community pharmacists
Answers for crossword on page 68.
Across: 3. Anaesthesia, 6. NOAC, 7. Rio,
8. Mousetrap, 9. Venous, 10 Amok, 12.
Sputum, 14. Double, 15. Coagulation, 17.
Down: 1. Thromboembolism, 2. Hi, 3.
Atrial, 4. Stroke, 5. Anaemia, 11. Knees,
13. PI, 14. DVT, 15. Clot, 16. Oral.
Betadine Sore Throat
Betadine, has launched Betadine Sore
Throat Lozenges to provide consumers
with another option in their battle
against a sore throat. Mike Abbott,
Head of OTC Marketing and Innovation
for Sanofi Consumer Healthcare
(the Australian distributor of Betadine)
said: ‘Australians told us they want an
on the go solution for relief of sore
throats. In response Betadine now
offers Betadine Sore Throat Lozenges an
antibacterial, on the go solution for fast,
soothing and effective relief from the
discomfort of a sore throat.’
Mr Abbott said Betadine Sore Throat
Lozenges were a companion product
to Betadine Sore Throat Gargle. ‘People
can use Betadine Sore Throat Lozenges
throughout the day for effective relief
and to help kill bacteria which can cause
sore throat and minor mouth infection.’
Mr Abbott said the launch of Betadine
Sore Throat lozenges would be
supported by a campaign featuring the
Betadine bacterium, Brutus. ‘Brutus has
been popular with our consumers
over the past year. We’re excited to be
bringing him back again this year to
see how he deals with the appearance
of anti-bacterial Betadine Sore
The launch will also be supported
by a range of point of sale material
available as well as in-store training for
pharmacists and pharmacy assistants.
Otsuka Australia Pharmaceutical Pty Ltd
has advised that it assume sponsorship
of Abilify (aripiprazole) tablets from
Bristol-Myers Squibb in Australia on 21
April. The new medical information and
pharmacovigilance reporting contact
details relating to Abilify tablets took
effect from 21 April and are: Australia Toll
Free: 1800 059 606, Facsimile: 03 9429
3234, email: OAPMedical@au.otsuka.
com . In Australia, Lundbeck and Otsuka
will continue to co-commercialise Abilify
Maintena (aripiprazole) which was
recently listed on the Pharmaceutical
Benefits Scheme. Otsuka Australia
Pharmaceutical announced it had
opened in Australia in January 2015,
becoming the first Oceania office of
Otsuka Pharmaceutical Co, Japan’s
second largest pharmaceutical company.
Links Archive Australian Pharmacist April 2015 Australian Pharmacist June 2015 Navigation Previous Page Next Page